AbbVie stock falls toward a 6-week low after adjusted profit fell short of expectations, but the full-year outlook was raisedMarket Watch • 04/27/23
Hagens Berman: Class Action Accuses AbbVie Inc. of Unfair Pricing of Autoimmune Drug Humira Following 470% Cost IncreaseBusiness Wire • 04/26/23
AbbVie Announces Late-Breaking Results from Phase 3 Trial Evaluating Atogepant (QULIPTA®) for the Preventive Treatment of Episodic Migraine Among Patients with Prior Treatment Failure at the 2023 AAN Annual MeetingPRNewsWire • 04/21/23
AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Moderately to Severely Active Crohn's DiseasePRNewsWire • 04/17/23
AbbVie Invites College Students Living with Cystic Fibrosis to Apply for the AbbVie CF Scholarship for the 2023-2024 Academic School YearPRNewsWire • 04/12/23